{"id":40,"date":"2025-06-19T18:59:05","date_gmt":"2025-06-19T18:59:05","guid":{"rendered":"https:\/\/firdapsehcp-calems.local\/calems\/?page_id=29"},"modified":"2025-12-22T14:52:28","modified_gmt":"2025-12-22T14:52:28","slug":"about-ca-lems","status":"publish","type":"page","link":"https:\/\/firdapsehcp.com\/ca-lems\/about-ca-lems\/","title":{"rendered":"ABOUT CANCER-ASSOCIATED LEMS SCLC"},"content":{"rendered":"\n
\n
\n
\"\"<\/figure><\/div><\/div>\n<\/div>\n\n\n\n
\n

Progressive and debilitating, Cancer-Associated LEMS small cell lung cancer (SCLC) is the most common antibody-mediated neurologic paraneoplastic syndrome in SCLC.4,5,8<\/sup><\/strong><\/p>\n<\/div>\n<\/div><\/div>\n\n\n\n

Because of reduced acetylcholine (ACh) release from presynaptic motor nerve terminals, patients with Cancer-Associated LEMS SCLC experience severe muscle weakness and other symptoms.9<\/sup><\/p>\n\n\n\n

\"\"<\/figure><\/div><\/div>\n\n\n
    \n
  1. In patients with LEMS, autoantibodies target voltage-gated calcium channels on the presynaptic motor neuron, reducing calcium influx during an action potential9<\/sup><\/span><\/li>\n\n\n\n
  2. Reduced intracellular calcium limits presynaptic vesicle fusion and release of ACh9<\/sup><\/span><\/li>\n\n\n\n
  3. Disrupted ACh transmission results in decreased activation of receptors on the postsynaptic membrane9<\/sup><\/span><\/li>\n\n\n\n
  4. Reduced ACh signaling results in diminished muscle fiber contraction and muscle weakness9<\/sup><\/span><\/li>\n<\/ol>\n\n\n\n
    \"\"<\/picture>
    \t\t\t\t
    \n\t\t\t\t\t\t\t\t\t\t\n
    \n\t
    \n\t\t\t\t\n\t<\/div>\n\n\t
    \n\t\t\t\t\t

    A simple, readily available, and affordable VGCC-Ab blood test, both P\/Q and N types, can confirm a Cancer-Associated LEMS SCLC diagnosis5,6<\/sup><\/h3>\n\t\t\t\t\t<\/div>\n\n\t
    \n\t\t\n\t\t\tRequest a test\t\t<\/a>\n\t<\/div>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div><\/div><\/div>\n\n\n\n
    \n

    A LARGE POPULATION GOES UNDIAGNOSED<\/h2>\n\n\n\n

    Even though Cancer-Associated LEMS SCLC affects a small percentage of people with small cell lung cancer (SCLC), a retrospective claims analysis suggests that >90% of Cancer-Associated LEMS SCLC cases may not receive a LEMS diagnosis.5,10<\/sup><\/strong><\/p>\n\n\n\n

    \n
    \n
    \"\"<\/figure><\/div><\/div>\n<\/div>\n\n\n\n
    \n
    \"\"<\/figure><\/div><\/div>\n\n\n\n

    *Based on retrospective US claims (2014-2022), SCLC was inferred using treatment proxies, and LEMS was identified through diagnosis codes. The observed diagnosis rate was 0.16% (0.19% sensitivity analysis). While US prevalence data is limited, historical non-US prospective studies estimate SCLC-LEMS as app. 3%-6%.10<\/sup><\/p>\n<\/div>\n<\/div><\/div>\n\n\n\n

    LEMS presents with symptoms SCLC patients commonly experience, such as fatigue, weakness, and restricted mobility11,12<\/sup><\/strong><\/p>\n\n\n